Trial Profile
Phase II study of irinotecan and amrubicin for relapsed non-small-cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2012
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Irinotecan (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Mar 2012 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 05 Jun 2009 New trial record.